Skip to main content

Table 3 Associations between rosiglitazone use and gastric cancer risk in a population-based nested case–control study

From: Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case–control study

Variables Rosiglitazone
Cases Controls Crude OR Adjusted OR Adjusted OR
N = 357 % N = 1,428 %
Nonuse 323 90.5 1,217 85.2 1.00 1.00 1.00
Any use 34 9.5 211 14.8 0.61* 0.75 1.21
  Recent use 10 2.8 25 1.8 1.51 1.50 1.88
  Past use 24 6.7 186 13.0 0.49* 0.62* 0.93
Cumulative dosage  
  < 260 DDDs 23 6.4 94 6.6 0.92 1.14 1.69
  ≥ 260 DDDs 11 3.1 117 8.2 0.35* 0.44* 0.79
Cumulative duration  
  < 1 year 26 7.3 116 8.1 0.85 1.04 1.56
  ≥ 1 year 8 2.2 95 6.7 0.32* 0.40* 0.74
  1. : Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding history, Helicobacter pylori eradication rate, and comorbidities.
  2. : Multivariate model adjusted for age, sex, peptic ulcer history, ulcer bleeding history, Helicobacter pylori eradication rate, comorbidities, and medications.
  3. OR odds ratios, N number.
  4. *P < 0.05.